Understand the source comparison
SS-LUP-332 for Muscle Preservation: Comparison of Research Applications
Hindlimb suspension (rodent) Soleus muscle mass, fiber CSA 30–40% atrophy reduction 7–14 days PPARδ activation maintains oxidative metabolism during unloading Effect is fiber-type specific. Glycolytic muscles show minimal protection Bed rest analog (primate or
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Hindlimb suspension (rodent)
- Soleus muscle mass, fiber CSA
- 30–40% atrophy reduction
- 7–14 days
- PPARδ activation maintains oxidative metabolism during unloading
- Effect is fiber-type specific. Glycolytic muscles show minimal protection
- Bed rest analog (primate or human pilot)
- Whole-body lean mass, VO2 max
- Preliminary data suggest 15–25% preservation
- 21–60 days
- Oxidative capacity preservation may maintain functional capacity during prolonged inactivity
- Dosing in larger species not fully optimized; compliance in human studies is challenging
- Post-surgical immobilization (rodent limb casting)
- Return to baseline strength, muscle mass recovery time
- 20–30% faster recovery vs control
- 14 days immobilization + 14 days reloading
- Metabolic preservation during immobilization accelerates anabolic response during reloading
- Cast models produce less severe atrophy than suspension, reducing observable effect size
- Cachexia models (tumor-bearing rodents)
- Muscle mass, grip strength
- Variable. 10–30% depending on tumor type
- 14–28 days
- PPARδ activation partially counters inflammatory signaling from tumor-derived cytokines
- Does not address tumor burden itself; cachexia involves multiple pathways beyond oxidative dysfunction
- Aging sarcopenia (aged rodents)
- Muscle mass, mitochondrial enzyme activity
- 15–25% improvement in oxidative capacity
- Chronic (60–90 days)
- Aging-related mitochondrial decline is partially reversible with sustained PPARδ activation
- Chronic dosing required; effects diminish if dosing stops
- SS-LUP-332 for muscle preservation is most effective in models where oxidative metabolism is the primary driver of atrophy. Disuse, immobilization, and microgravity analogs. It is less effective in models where atrophy is driven by inflammatory signaling (sepsis), neural loss (denervation), or energy deficit (caloric restriction). Researchers should match the compound to the mechanistic question rather than applying it generically to all atrophy models.